The Criteria for the clinical use of immunoglobulin in Australia (the Criteria) undergoes periodic review to reflect the latest scientific evidence and expert advice from our National Immunoglobulin Governance Advisory Committee and its Specialist Working Groups.
This page summarises the changes to the Criteria which were implemented in December 2024. Changes are applied immediately to new authorisations and to existing authorisations at the next continuing treatment request, unless otherwise stated. For more information about any of these changes, please contact the Ig Governance team at IgGovernance@blood.gov.au.
Acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT) – Version 3.4
- Updated the conditions for additional dose to clarify that the clinician should provide the patient’s current IgG level.
Inborn errors of immunity (IEI) with antibody deficiency (formerly primary immunodeficiency diseases) – Version 3.5
- Changed all instances of ‘primary immunodeficiency diseases’ to ‘inborn errors of immunity’.
- Updated the conditions for additional dose to clarify that the clinician should provide the patient’s current IgG level.
- Other minor typographical changes.
Secondary hypogammaglobulinaemia unrelated to haematological malignancy or haemopoietic stem cell transplant (HSCT) – Version 3.5
- Updated the conditions for additional dose to clarify that the clinician should provide the patient’s current IgG level.
- Other minor typographical changes.
Specific antibody deficiency – Version 3.3
- Clarified maximum dose per period per kg.
Toxic epidermal necrolysis (TEN; Lyell syndrome)/Stevens-Johnson syndrome (SJS) – Version 3.1
- Minor typographical changes.
Vaccine associated myocarditis and pericarditis (VAMP) – Version 3.1
- Clarified qualifying criteria to explain that vaccine should be given within the past 20 days.
Last updated: 03 Feb 2026